Effect of targeted ovarian cancer therapy using amniotic fluid mesenchymal stem cells transfected with enhanced green fluorescent protein-human interleukin-2 in vivo by anvari, saeed
Effect of targeted ovarian cancer 
therapy using amniotic fluid
mesenchymal stem cells 
transfected with enhanced green 
fluorescent protein-human 
interleukin-2 in vivo
YUAN YAO , YUANLONG ZHANG2, SONGBIN
Year:2015, MOLECULAR MEDICINE REPORTS
Presenter: Anvari.s
LogoType
Agenda Style
01
02
03
04
05
.Introduction
Material and method
.Result
Reference
.Discussion
Introduction
Introduction 
.    
In our previous studies, the SKOV3 h
uman ovarian carcinoma cell line[3]
Ovarian cancer is one of the most let
hal types of gynecological malignanc
chemotherapy is poor in recurrent pati
ents[1]
aim of current research is to establi
sh novel therapeutic methods
Cell lines and animal models are valu
able research tools[2]
introduction
IL-2
Function[4,5]
Increase[6]
 stimulating the proliferation of T cells
 inducing cytotoxic T lymphocyte generation
 inducing the production of natural killer cells
In cancer, including ovarian cancer, metastatic 
melanoma and renal cell carcinoma
cytocine
Introduction 
.
 when IL-2 is administered systemically at high doses have
side effect:
 malaise, fever, nausea, and vomiting[7]
 more severe reactions, hepatic dysfunction, increased capill
ary permeability and decreased systemic vascular resistanc
e[8]
 therapeutic strategy that specifically delivers IL-2 to the tum
or location may significantly reduce the required IL-2 dosage
introduction
. 
. 
stem cells are becoming an im
portant source of cells for cellul
ar therapy[9]
mesenchymal stem cells is
olated from human second a
nd third trimester AF and
IL-2 and the green fluorescent prot
ein (GFP) gene fused form a plas
mid vector,transfect to MSC
intravenously injected at various doses i
nto ovarian cancer nude mice
Tumor formation, the expression hIL-2 
were analyzed
The aim of the study evaluate the migrato
ry AF-MSCs into tumor cells in vivo, deter
mine their function as delivery vehicles for 
anti-tumor molecules, such as IL-2
Material method and Result
Isolation and culture of MSCs
.
 ethical approval.
 consent was obtained from each volunteer
 AF samples from 30 female volunteers
 The samples centrifuged at 100 g for 5 
min
 DMEM,FBS,Penestrep
 non-adhering cells were removed.
characterization Msc
 Markers of AF-MSCs analysied by RT-PCR
 Total RNA extracted from MSCs using Tri Reagent,onest
ep pcr
sence:5'-CGTGAAGCTGGAGAAGGAGAAGCTG-3'
 Primers oct 4 
anti sense:5'-CAAGGGCCGCAGCTTACACATGTTC-3‘
sense: 5’;TGGCACCACACCTTCTACAATGAGC-3’
 Primers B-actine
anti sense:5'-GCACAGCTTCTCCTTAATGTCACGC-3' 
1)Oct4 are transcription factor
s It is critically involved in the s
elf-renewal of undifferentiate
d stem cells wiki
2)Tri reagent:guanidinium thioc
yanate-phenol-chloroform 
characterization Msc
1)Oct4 are transcription factors It is crit
ically involved in the self-renewal of un
differentiated stem cells
2)Highly expressed in SC,emberyonic c
arcinoma cell,emberyonic germ cell.
 NTERA-2 cells  line a pluripotent embry
onic carcinoma as positve controll
 MRC-5 cells line a human diploid fibrobl
asts lung tissue as negative controls
EGFP gene transfection into MSCs
.
 40-micro l Lipofectamine 20 h mixe
d with AF_MSC
 One week later, the stable transfec
tants were selected with G418 
 expression of EGFP in the cell mo
nitored under UV microscope
GFP
Neo/kana
G418 blocks polypeptide synthesis by in
hibiting the elongation step in both proka
ryotic and eukaryotic.
hIL-2 gene extraction
.
 Peripheral blood samples
 lymphocyte separating medium c
entrifuged at 150 x g for 15 min
 First layer, plasma; second layer, 
lymphocytes and monocytes; thir
d layer, lymphocyte
 broken down using TRIzol.Rna e
xtract. RT-PCR was performed t
o synthesize cDNA(462 bp) Upstreamprimer:5'GGAATTCATGTACAGGATG3‘
Downstream primer:5'GACTGAACTCAGCTGG3'
hIL-2 gene identification
.
hIL-2 gene segment cloning and identification.
.
 product was combined with a 
pMD18-T Simple Vector
 JM109 competent cells,heat
shoke
 spread on (LB) agar plates wi
th X-gal, digested with EcoR
Ⅰand SalⅠ, electrophoresis 
was performed
transfection of pMD-hIL-2 into AF-MSCs
.
 AF-MSCs were inoculated during the 
logarithmic growth phase
 pMD-hIL-2 was transfected into the A
F-MSCs using Lipofectamine
 the cells were selected using 500 μg/
ml G418
 hIL-2 detection kit, GFP gene expres
sion detected fluorescence microsco
pe
transfection of pMD-hIL-2 into AF-MSCs
.
 AF-MSCs were inoculated during the 
logarithmic growth phase
 pMD-hIL-2 was transfected into the A
F-MSCs using Lipofectamine
 the cells were selected using 500 μg/
ml G418
 hIL-2 detection kit, GFP gene expres
sion detected fluorescence microsco
pe
experssion il-2
.
Establishing an ovarian cancer animal  
.
 SKOV3 ovarian cancer cells
 nu/nu-BALB/c nude mouse
 subcutaneously injected into the scap
ula region.
 2 or 18 days before tumor cells inocul
ation
 tumor reached 1 cm in diamet
er
 AF-MSCs transiently transfect
ed, pMD-hIL-2 were injected t
he caudal vein of each ovaria
n cancer mouse
 Six weeks green fluorescence 
was apparent around the tum
or tissue
Establishing an ovarian cancer animal  
.
Ultrastructure examination of ovarian cancer cells.
.
Discusstion
. Ovarian cancer is a common type of 
malignant tumor
 threatens the physical and mental he
alth of females
 majority of patients reached an adva
nced stage when they are diagnosed
 IL-2 administration stimulates T cell p
roliferation[10]
 physicians attempted to use IL-2 
to cure patients suffering with me
tastasized ovarian cancer
 high concentrations of IL-2 are re
quired
 MSCs systemic or local administr
ation has been investigated in a v
ariety of tumor animal models
. AF-MSCs may be considered as a po
werful tool for gene therapy
 In the present study, AF-MSCs transd
uced with GFP were analyzed in a m
ouse ovarian cancer model to evaluat
e the migratory properties in vivo
 in the present study intravenousl
y injected AF-MSCs, that stably e
xpress hIL-2, 
 are able to trace the subcutaneo
usly transplanted ovarian tumor c
ells, and secrete IL-2 locally, resu
lting in the apoptosis of the tumor 
cells.
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